Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone for diabetic retinopathy (DeFineDR)
NCT04795726Completed
- Sponsor
- Bayer
- Start
- Mar 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Randomised, double-blind trial of finerenone in diabetic retinopathy (DR) (2 arms), sponsored by Bayer. Primary endpoint: Proportion of participants with progression of non-proliferative diabetic retinopathy (NPDR) at 2 years. Started Mar 2021; status: completed.
02
Drugs
finerenone
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT04795726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04795726.